Abstract
Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) represent a novel class of compounds that hold promise as agents for the control of colon cancer. They are derivatives of conventional NSAIDs that have been modified by adding to them, via a spacer molecule, a nitric oxide releasing moiety. The expectation is that the combined effects of NO and the NSAID moiety will exceed those of each structural component alone. Extensive work has demonstrated their potency and efficacy in preclinical models of colon cancer. The mechanism of action of NO-NSAIDs involves the modulation of several critical cellular signaling pathways, whereas the induction of a state of oxidative stress, at least by NO-aspirin, appears to be a major proximal event. Clinical trials are needed to assess the role of NO-NSAIDs in the control of colon cancer.
Similar content being viewed by others
Article PDF
References
Author X . Statistics for 2006. City of publication: American Cancer Society; 2006.
Ignarro LJ . Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002; 53: 503–14.
Pacher P, Beckman JS, Liaudet L . Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315–424.
Rao CV . Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004; 555: 107–19.
Hirst D, Robson T . Targeting nitric oxide for cancer therapy. J Pharm Pharmacol 2007; 59: 3–13.
Ying L, Hofseth LJ . An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007; 67: 1407–10.
Roberts J II, Morrow J . Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment gout. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p687–31.
Tashjian AH Jr, Voelkel EF, Goldhaber P, Levine L . Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglan-din-producing fibrosarcoma. Prostaglandins 1973; 3: 515–24.
Thun MJ, Henley SJ, Patrono C . Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–66.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–90.
Shiff SJ, Qiao L, Tsai LL, Rigas B . Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491–503.
Shiff SJ, Rigas B . The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) [comment]. J Exp Med 1999; 190: 445–50.
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237–45.
Rayyan Y, Williams J, Rigas B . The role of NSAIDs in the prevention of colon cancer. Cancer Invest 2002; 20: 1002–11.
del Soldato P, Sorrentino R, Pinto A . NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 20: 319–23.
Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005; 312: 978–88.
Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B . Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001; 61: 3285–9.
Ouyang N, Williams JL, Rigas B . NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR) {delta} expression in APCmin/+ mice proportionally to their tumor inhibitory effect: Implications for the role of PPAR{delta} in carcinogenesis. Carcinogenesis 2006; 27: 232–9.
Gao J, Liu X, Rigas B . Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxi-dative stress. Proc Natl Acad Sci USA 2005; 102: 17207–12.
Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998; 62: L367–73.
Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B . NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 2004; 313: 784–8.
Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006; 5: 1530–8.
Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L . Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther 2006; 5: 919–26.
Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A . Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124: 600–7.
Iconomou G, Kalofonos HP, Koutras AK, Vagenakis AG, Rigas B . Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain. J Support Oncol 2006; 4: 168.
Rigas B, Kashfi K . Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004; 10: 324–30.
Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003; 63: 7613–8.
Gao J, Kashfi K, Liu X, Rigas B . NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 2006; 27: 803–10.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a NIH 2R01 CA92423 grant.
Rights and permissions
About this article
Cite this article
Kozoni, V., Rosenberg, T. & Rigas, B. Development of novel agents based on nitric oxide for the control of colon cancer. Acta Pharmacol Sin 28, 1429–1433 (2007). https://doi.org/10.1111/j.1745-7254.2007.00696.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00696.x
Keywords
This article is cited by
-
Comparative Proteomic Analysis of Cysteine Oxidation in Colorectal Cancer Patients
Molecules and Cells (2013)
-
Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles
Pharmaceutical Research (2012)
-
Ist psychischer Stress ein Risikofaktor bei der Entstehung und Entwicklung von Tumoren?
Der Onkologe (2009)